DexCom, Inc. (NASDAQ:DXCM) produced a 185.77% rally since recording the worst price of $52.92. Thanks to the latest 3.92% increase, it now trades at $151.23. Throughout the trading on 02/11/2019, the share price floated between $147.2927 and $153.32. This company shares are -0.73% up from its target price of $150.13 and the current market capitalization stands at $13.29B. The recent change has given its price a 15.2% lead over SMA 50 and -0.96% deficit over its 52-week high. The stock witnessed 6.58% gains, 4.55% gains and 22.76% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found DXCM’s volatility during a week at 3.29% and during a month it has been found around 3.27%.

DexCom, Inc. (DXCM) Top Holders

Institutional investors currently hold around $13.11 billion or 0% in DXCM stock. Look at its top three institutional owners. Vanguard Group Inc owns $1.16 billion in DexCom, Inc., which represents roughly 8.7% of the company’s market cap and approximately 8.82% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 6,374,238 shares of the stock are valued at $927.64 million. The third largest holder is Morgan Stanley, which currently holds $797.26 million worth of this stock and that ownership represents nearly 6% of its market capitalization.

DexCom, Inc. 13F Filings

At the end of September reporting period, 206 institutional holders increased their position in DexCom, Inc. (NASDAQ:DXCM) by some 13,417,260 shares, 162 decreased positions by 13,305,766 and 39 held positions by 63,353,355. That puts total institutional holdings at 90,076,381 shares, according to SEC filings. The stock grabbed 92 new institutional investments totaling 7,132,367 shares while 28 institutional investors sold out their entire positions totaling 422,927 shares.

DexCom, Inc. (NASDAQ:DXCM) Insider Trades

Multiple company employees have indulged in significant insider trading. DexCom, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP, Strategy & Corp. Dev. Pacelli Steven Robert has sold 3,114 shares of DexCom, Inc. (DXCM) in trading session dated Jan. 23, 2019. These shares are worth $466,290 and were traded at $149.74 each. The SEC filing shows that Kahn Barbara performed a sale of 10,631 shares. The Director disposed these shares by way of transaction on Jan. 14, 2019. The company’s shares were given away at $142.3 per share worth to an income of some $1,512,791 on account of Kahn Barbara.

President, CEO & Chairman, Sayer Kevin R, sold 6,000 common shares of DexCom, Inc. (DXCM) in the open market. In a transaction dated Jan. 14, 2019, the shares were put up for sale at an average price of $140.99, raking in a sum of $845,940. After this sale, 314,837 common shares of DXCM are directly owned by the insider, with total stake valued at $47,612,800.

In the transaction dated Jan. 10, 2019, the great number of shares disposed came courtesy the SVP, GC & Chief Compliance Off; Murphy Patrick Michael disposed a total of 400 shares at an average price of $138.75, amounting to approximately $55,500. The insider now directly owns 29,708 shares worth $4,492,741.

DexCom, Inc. (DXCM) Analyst Guide

Several analysts have released their opinion on DexCom, Inc. (NASDAQ:DXCM), with 9 analysts believing it is a strong buy. Whereas 6 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.85 average brokerage recommendation.